NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced the appointment of David Wambeke as Chief Business Officer, effective March 1, 2026. Concurrent with his appointment, Wambeke purchased 1,000,000 shares of NeuroOne common stock at $0.6704 per share, representing the closing price on February 27, 2026. This insider purchase demonstrates strong conviction in the company's strategic direction and growth prospects.
Wambeke will lead NeuroOne's drug delivery program and collaborate with the executive team to advance clinical development and commercialization. His responsibilities include refining product requirements for preclinical and clinical-stage devices, expanding relationships with key opinion leaders, and engaging prospective pharmaceutical partners to maximize the value of the company's drug delivery platform. He will also oversee investor relations and support strategic business development initiatives, including partnerships and corporate transactions.
"David brings a rare combination of public company experience, capital markets expertise, and a demonstrated ability to translate strategic vision into operational and clinical execution," said Dave Rosa, CEO of NeuroOne. "As we continue to execute on our strategy and expand awareness of NeuroOne's technology platform, we believe David will be instrumental in sharpening our messaging, deepening investor engagement, and advancing business development activities that support long-term value creation."
Wambeke previously served as Chief Business Officer at DiaMedica Therapeutics, where he led the expansion of a lead biologic into preeclampsia and oversaw a successful Phase 2 clinical trial. Prior to that, he spent 16 years at Craig-Hallum Capital Group in life sciences investment banking, advising healthcare companies on equity financings, M&A, and strategic transactions. He began his career in the U.S. Army, was wounded in combat in Baghdad, and awarded the Purple Heart.
The company also granted Wambeke an inducement stock option to purchase 500,000 shares at $0.6704 per share, vesting over four years. The proceeds from the share sale will support ongoing clinical and product development activities, as well as working capital and general corporate purposes.
NeuroOne markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System, and OneRF® Trigeminal Nerve Ablation System. The company is also engaged in research and development for drug delivery and spinal cord stimulation programs. For more information, visit nmtc1.com.
This appointment and insider purchase underscore NeuroOne's commitment to advancing its technology platform and expanding into new therapeutic areas. With a strategic partnership with Zimmer Biomet and four cleared devices, the company aims to scale commercialization and explore opportunities in basivertebral ablation, drug delivery, and spinal cord stimulation.
